Clinical Data Repinex2020-03-23T16:31:14+00:00

HEALTHCARE PROFESSIONALS
RepNewBanner

Clinical Data

Three bioequivalence clinical trials were performed comparing Repinex® XL 2mg prolonged-release tablets with Requip® Modutabs (ropinirole) 2mg (GlaxoSmithKline, Munich, Germany) and one bioequivalence study was performed comparing Repinex XL 8mg prolonged-release tablets and Requip Modutabs 8mg.1

Single dose study comparing Repinex XL 2mg and Requip XL 2mg under fasted conditions

2mg-single-state-fasting-conditions3

Single dose study comparing Repinex XL 2mg and Requip XL 2mg under fed conditions

2mg-single-state-fed-conditions3

Steady state study comparing Repinex XL 2mg and Requip XL 2mg under fasted conditions

Steady-state-2mg-fasting3

Single dose study comparing Repinex XL 8mg and Requip XL 8mg under fasted conditions

Single-dose-8mg-fasting-state3

References: 1) Data on file. 1010067149 v 4.0 October 2019.

TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Repinex XL, please see the abbreviated prescribing information.

Revision reference – Repinex XL_18_23.03.2020

More products available
in this range:
Click to view their
individual websites